7AA Limited Human
Selank
Russia-approved anxiolytic heptapeptide derived from tuftsin — benzodiazepine-grade anxiety relief without sedation or dependence.
In Plain English: Selank is a synthetic 7-amino-acid peptide derived from tuftsin, a fragment of human IgG. Approved in Russia since 2009 for generalised anxiety, it delivers anxiety relief without sedation, dependence, or cognitive blunting. It works by modulating GABA-A receptors, boosting serotonin turnover, prolonging enkephalin activity, and raising BDNF in the hippocampus.
Research Maturity
Limited Human (135 results on PubMed for 'selank' (verified 2026-05-04)+ Studies)
Quick Facts
Focus
Anxiety & Mood
Cognition
Stress Modulation
Route
IV
Nasal
Origin
Synthesised at the Institute of Molecular Genetics, Russian Academy of Sciences. C-terminally extended analogue of tuftsin (Thr-Lys-Pro-Arg) with Pro-Gly-Pro added for metabolic stability. Approved in Russia (2009) as nasal spray for GAD and neurasthenia.
Mechanism
Positive allosteric modulator of GABA-A receptors (upregulates alpha2, alpha3, gamma2 subunits) without occupying the benzodiazepine site. Inhibits aminopeptidase N and DPP-IV, prolonging endogenous enkephalin. Normalises dopamine under stress, increases serotonin turnover, upregulates BDNF in hippocampus and PFC. Immunomodulatory via tuftsin lineage (reduces IL-6, TNF-a).
Outcome
RCT (N=62): matched medazepam on Hamilton Anxiety Scale reduction with additional antiasthenic and mild psychostimulant effects. No tolerance, no withdrawal, no sedation in any published trial. Cognitive improvements in elderly (28-day study).
Safety Flags & Warnings
Limited Long-Term Western Data
CNS Depressant Potentiation
Nasal Irritation
Always consult a licensed physician. Research purposes only.
€6.5 / mg
